I. Paul Singh, MD; and Nandini Venkateswaran, MD
Show Description +
Innovations in treatment of corneal disease affecting the front and back surface has lagged behind other areas of ophthalmology. That all may change soon. Nandini Venkateswaran, MD, gives a lowdown on recent studies looking at using engineered fibroblast growth factors (FGFs)—which are proven to improve healing while offering protective effects—in treatment of endothelial and epithelial cell defects affecting the cornea.
Posted: 8/31/2023
I. Paul Singh, MD; and Nandini Venkateswaran, MD
Innovations in treatment of corneal disease affecting the front and back surface has lagged behind other areas of ophthalmology. That all may change soon. Nandini Venkateswaran, MD, gives a lowdown on recent studies looking at using engineered fibroblast growth factors (FGFs)—which are proven to improve healing while offering protective effects—in treatment of endothelial and epithelial cell defects affecting the cornea.
Posted: 8/31/2023
Supported by
Please log in to leave a comment.